A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 9262 participants.

Also called NCT07551492

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 9,262 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07551492
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07551492. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-29 (actual); primary completion 2031-05-24 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
HRS9531
Intervention (Drug)
HRS9531 placebo
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07551492
Content hash
9117a510513436e4dcf762b52df2531e6fe180e679c9d530eaa4bac9fab4422a